Ozempic Is Changing America’s Obesity Fight – PJ Media
For years, the United States has struggled against a stubborn rise in obesity rates. However, recent data suggests a promising shift as GLP-1 medications begin to impact national health trends.
Prescriptions for GLP-1 drugs, including semaglutide and tirzepatide, saw a significant increase. Between the second quarter of 2021 and the first quarter of 2026, prescriptions rose from 1,884 to 8,819 per 100,000 adult patients.
A Measurable Decline in Obesity
This pharmaceutical shift coincides with a decline in obesity percentages. The share of adults classified as obese fell from 42.3% to 40.7% during a similar period, while the healthy weight share increased from 25.1% to 25.6%.
Another national survey indicates an even more pronounced change. Adult obesity was recorded at 39.9% in 2022 and dropped to 37% by 2025, meaning roughly 7.6 million fewer adults met the obesity standard over those three years.
The Science and the Shift in Care
The development of these treatments took decades of research. Habener and Mojsov identified the active form of GLP-1, while Knudsen helped transform that discovery into weight-loss medicines.
The availability of these shots has altered how patients approach weight loss. While bariatric surgery rates rose through 2023, they dropped in 2024 and 2025 as more people opted for medication first.
Analysis shows GLP-1 prescriptions rose from 0.03% to 5.3% over seven years. Despite this, a significant gap in care remains, as more than 90% of patients in one study received no obesity treatment at all.
Barriers to Long-Term Success
The promise of GLP-1 drugs comes with significant hurdles. Currently, about 12% of U.S. Adults report using these medications, but many discontinue use due to side effects, high costs, or lack of insurance coverage.
Stopping these medications may lead to weight regain. Discontinuation could increase the risk of chronic conditions, such as cardiovascular disease or type 2 diabetes.
Looking Forward
Future obesity rates may depend on how these barriers to medication are addressed. While lower obesity rates are a positive indicator, diabetes diagnoses still reach 13.8%, indicating a complicated health landscape.
The nation may continue to see a downward trend if patients can remain under medical supervision. However, the long-term impact could be limited by decades of sedentary work, cheap calories, and medical neglect.
Frequently Asked Questions
What are GLP-1 medicines?
GLP-1 medicines are weight-loss treatments, such as semaglutide and tirzepatide, that were developed following research into the active form of GLP-1.
Why do some patients stop taking GLP-1 drugs?
Patients often stop using these medications due to side effects, the high cost punishing family budgets, or a lack of health insurance coverage.
What is the risk of discontinuing GLP-1 therapy?
Discontinuing the drugs can lead to weight regain and an increased risk of developing cardiovascular disease or type 2 diabetes.
Do you believe medical interventions are the most effective way to address national obesity trends?